495 related articles for article (PubMed ID: 24510095)
1. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
Cairoli E; Eller-Vainicher C; Ulivieri FM; Zhukouskaya VV; Palmieri S; Morelli V; Beck-Peccoz P; Chiodini I
Osteoporos Int; 2014 Apr; 25(4):1401-10. PubMed ID: 24510095
[TBL] [Abstract][Full Text] [Related]
2. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
Brown JP; Roux C; Ho PR; Bolognese MA; Hall J; Bone HG; Bonnick S; van den Bergh JP; Ferreira I; Dakin P; Wagman RB; Recknor C
Osteoporos Int; 2014 Jul; 25(7):1953-61. PubMed ID: 24676847
[TBL] [Abstract][Full Text] [Related]
3. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
[TBL] [Abstract][Full Text] [Related]
4. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.
Naylor KE; Jacques RM; Paggiosi M; Gossiel F; Peel NF; McCloskey EV; Walsh JS; Eastell R
Osteoporos Int; 2016 Jan; 27(1):21-31. PubMed ID: 25990354
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.
Paggiosi MA; Peel N; McCloskey E; Walsh JS; Eastell R
Osteoporos Int; 2014 Dec; 25(12):2729-41. PubMed ID: 25074351
[TBL] [Abstract][Full Text] [Related]
6. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
Ringe JD; Möller G
Rheumatol Int; 2009 Dec; 30(2):213-21. PubMed ID: 19430791
[TBL] [Abstract][Full Text] [Related]
7. Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study.
Leslie WD; Martineau P; Bryanton M; Lix LM
Osteoporos Int; 2019 Jul; 30(7):1445-1453. PubMed ID: 31016351
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice.
Baxter I; Rogers A; Eastell R; Peel N
Osteoporos Int; 2013 Mar; 24(3):941-7. PubMed ID: 22872068
[TBL] [Abstract][Full Text] [Related]
9. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
Välimäki MJ; Farrerons-Minguella J; Halse J; Kröger H; Maroni M; Mulder H; Muñoz-Torres M; Sääf M; Snorre Øfjord E
Clin Ther; 2007 Sep; 29(9):1937-49. PubMed ID: 18035193
[TBL] [Abstract][Full Text] [Related]
10. Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension.
Zhang ZL; Liao EY; Xia WB; Lin H; Cheng Q; Wang L; Hao YQ; Chen DC; Tang H; De Peng Y; You L; He L; Hu ZH; Song CL; Wei F; Wang J; Zhang L; Santora AC
Osteoporos Int; 2015 Sep; 26(9):2365-74. PubMed ID: 25929192
[TBL] [Abstract][Full Text] [Related]
11. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
[TBL] [Abstract][Full Text] [Related]
12. Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort.
Segaud N; Legroux I; Hazzan M; Noel C; Cortet B
Osteoporos Int; 2018 May; 29(5):1165-1175. PubMed ID: 29500526
[TBL] [Abstract][Full Text] [Related]
13. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.
Polyzos SA; Anastasilakis AD; Bratengeier C; Woloszczuk W; Papatheodorou A; Terpos E
Osteoporos Int; 2012 Mar; 23(3):1171-6. PubMed ID: 21305266
[TBL] [Abstract][Full Text] [Related]
14. Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women.
Frost ML; Siddique M; Blake GM; Moore AE; Marsden PK; Schleyer PJ; Eastell R; Fogelman I
Osteoporos Int; 2012 Aug; 23(8):2107-16. PubMed ID: 21983795
[TBL] [Abstract][Full Text] [Related]
15. The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis.
Zhu HM; Qin L; Garnero P; Genant HK; Zhang G; Dai K; Yao X; Gu G; Hao Y; Li Z; Zhao Y; Li W; Yang J; Zhao X; Shi D; Fuerst T; Lu Y; Li H; Zhang X; Li C; Zhao J; Wu Q; Zhao SJ
Osteoporos Int; 2012 Apr; 23(4):1317-27. PubMed ID: 21505910
[TBL] [Abstract][Full Text] [Related]
16. Fracture risk remains reduced one year after discontinuation of risedronate.
Watts NB; Chines A; Olszynski WP; McKeever CD; McClung MR; Zhou X; Grauer A
Osteoporos Int; 2008 Mar; 19(3):365-72. PubMed ID: 17938986
[TBL] [Abstract][Full Text] [Related]
17. Biochemical markers for bone turnover predict risk of vertebral fractures in postmenopausal women over 10 years: the Japanese Population-based Osteoporosis (JPOS) Cohort Study.
Tamaki J; Iki M; Kadowaki E; Sato Y; Chiba Y; Akiba T; Matsumoto T; Nishino H; Kagamimori S; Kagawa Y; Yoneshima H;
Osteoporos Int; 2013 Mar; 24(3):887-97. PubMed ID: 22885773
[TBL] [Abstract][Full Text] [Related]
18. Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients.
Geller JL; Hu B; Reed S; Mirocha J; Adams JS
Endocr Pract; 2008 Apr; 14(3):293-7. PubMed ID: 18463035
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.
Palomba S; Orio F; Manguso F; Falbo A; Russo T; Tolino A; Tauchmanovà L; Colao A; Doldo P; Mastrantonio P; Zullo F
Osteoporos Int; 2005 Sep; 16(9):1141-9. PubMed ID: 15928801
[TBL] [Abstract][Full Text] [Related]
20. Improved adherence with PTH(1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis.
Black DM; Bilezikian JP; Greenspan SL; Wüster C; Muñoz-Torres M; Bone HG; Rosen CJ; Andersen HS; Hanley DA
Osteoporos Int; 2013 Apr; 24(4):1503-11. PubMed ID: 22930240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
